JP7570174B2 - Emulsion stabilization method - Google Patents
Emulsion stabilization method Download PDFInfo
- Publication number
- JP7570174B2 JP7570174B2 JP2019221140A JP2019221140A JP7570174B2 JP 7570174 B2 JP7570174 B2 JP 7570174B2 JP 2019221140 A JP2019221140 A JP 2019221140A JP 2019221140 A JP2019221140 A JP 2019221140A JP 7570174 B2 JP7570174 B2 JP 7570174B2
- Authority
- JP
- Japan
- Prior art keywords
- emulsion
- weight
- water
- emulsion composition
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000839 emulsion Substances 0.000 title claims description 177
- 238000000034 method Methods 0.000 title claims description 52
- 230000006641 stabilisation Effects 0.000 title claims description 48
- 238000011105 stabilization Methods 0.000 title claims description 48
- 239000000203 mixture Substances 0.000 claims description 84
- 150000003839 salts Chemical class 0.000 claims description 42
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 claims description 19
- 229950010121 ufenamate Drugs 0.000 claims description 19
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 8
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- -1 alkyl methacrylate Chemical compound 0.000 description 41
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 29
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000004359 castor oil Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- 235000019438 castor oil Nutrition 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 4
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 4
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OHILSKSRDDTCIR-WKSAPEMMSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;hydrochloride Chemical compound Cl.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O OHILSKSRDDTCIR-WKSAPEMMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XTIUAXFQEAMQRU-UHFFFAOYSA-N 2-[4-(butylamino)benzoyl]oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCCNC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1 XTIUAXFQEAMQRU-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- GORMSINSWZJIKL-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-dimethylpropyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(C)(C)COC(=O)C(CC)CCCC GORMSINSWZJIKL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- WEHZQLDFDZDFRZ-UHFFFAOYSA-N ethylamino benzoate Chemical compound CCNOC(=O)C1=CC=CC=C1 WEHZQLDFDZDFRZ-UHFFFAOYSA-N 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229950007594 meprylcaine Drugs 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DVOUJRUFCBNRQW-UHFFFAOYSA-N mucoxin Chemical compound O1C(C(O)CCCCCCCCCCCCCCCCC)CC(O)C1C1OC(C(O)CCCCCC=2C(OC(C)C=2)=O)CC1 DVOUJRUFCBNRQW-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- 229960000986 oxetacaine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
本発明は、ウフェナマートの新たな用途に関し、具体的には、水溶性カルボン酸及び／又はその塩を含有する乳化組成物の乳化安定化のためのウフェナマートの用途に関する。 The present invention relates to a new use of ufenamate, specifically, to the use of ufenamate for emulsion stabilization of an emulsion composition containing a water-soluble carboxylic acid and/or its salt.
乳化組成物は、水性成分と油性成分を配合でき、様々な製剤処方に対応できると共に、皮膚に適用した際の使用感も優れている。このため、乳化組成物は、外用医薬品や化粧料の分野において汎用されている。 Emulsion compositions can be used to blend aqueous and oily ingredients, can be used in a variety of formulations, and have an excellent feel when applied to the skin. For this reason, emulsion compositions are widely used in the fields of topical medicines and cosmetics.
乳化組成物の水相には、美白効果、保湿効果、消炎効果、収斂効果、紫外線吸収効果等を期待して様々な機能性成分が配合される。このような機能性成分には、カルボキシル基を有する化合物が数多く知られており、例えば、アスコルビン酸、グリチルリチン酸ジカリウム、コンドロイチン硫酸ナトリウム、クエン酸、グルコン酸、コハク酸、乳酸、リンゴ酸、アミノ酸（特許文献１）、ピロリドンカルボン酸ナトリウム（特許文献１～４）等が挙げられる。 Various functional ingredients are blended into the aqueous phase of the emulsion composition in the hope of providing whitening, moisturizing, anti-inflammatory, astringent, UV absorbing, etc. Many compounds having a carboxyl group are known as such functional ingredients, and examples of such compounds include ascorbic acid, dipotassium glycyrrhizinate, sodium chondroitin sulfate, citric acid, gluconic acid, succinic acid, lactic acid, malic acid, amino acids (Patent Document 1), and sodium pyrrolidone carboxylate (Patent Documents 1 to 4).
特許文献１に記載の乳化組成物は、レシチン及び２－メタクリロイルオキシエチルホスホリルコリンと所定のモル分率のアルキルメタクリレートとの共重合体を必須とすることから、処方上の制約が大きく近年の多様化する乳化製剤の処方に対応できないケースがある。また、特許文献１に記載の乳化組成物のうち、実際に乳化安定性が確認された処方は上記のカルボキシル基を有する化合物の配合量が少ないことから、期待する効果が得られるほどに充分量の機能性成分を配合できないケースがある。 The emulsion composition described in Patent Document 1 requires lecithin and a copolymer of 2-methacryloyloxyethyl phosphorylcholine and a specified molar fraction of alkyl methacrylate, and therefore has significant formulation restrictions and may not be able to accommodate the increasingly diverse emulsion formulations of recent years. In addition, among the emulsion compositions described in Patent Document 1, the formulations for which emulsion stability has actually been confirmed contain a small amount of the above-mentioned compound having a carboxyl group, and therefore may not contain a sufficient amount of functional ingredients to achieve the expected effect.
また、特許文献２～４に記載の乳化組成物ピロリドンカルボン酸又はその塩が配合されてよいことが記載されているものの、実際に、ピロリドンカルボン酸又はその塩が配合された場合の乳化組成物の性状安定性については検討されていない。 In addition, although it is described in Patent Documents 2 to 4 that pyrrolidone carboxylic acid or a salt thereof may be blended in the emulsion compositions, the stability of the properties of the emulsion compositions when pyrrolidone carboxylic acid or a salt thereof is blended has not actually been examined.
発明は、水溶性カルボン酸及び／又はその塩を含む乳化組成物の乳化状態を安定化させるための新たな方法を提供することを目的とする。 The object of the invention is to provide a new method for stabilizing the emulsified state of an emulsion composition containing a water-soluble carboxylic acid and/or its salt.
本発明者は、水溶性カルボン酸及び／又はその塩を含む乳化組成物について鋭意検討を行ったところ、これまで乳化安定化効果が知られていなかったウフェナマートを配合することで、優れた乳化安定性が備わることを予期せずして見出した。本発明は、この知見に基づいて更に検討を重ねることにより完成したものである。 The inventors conducted extensive research into emulsion compositions containing water-soluble carboxylic acids and/or their salts, and unexpectedly discovered that excellent emulsion stability was achieved by incorporating ufenamate, which was not previously known to have an emulsion stabilizing effect. The present invention was completed through further research based on this finding.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． 水溶性カルボン酸及び／又はその塩を含む乳化組成物中に、前記水溶性カルボン酸及び／又はその塩と共に、ウフェナマートを配合する、乳化安定化方法。
項２． 前記乳化組成物が、前記水溶性カルボン酸及び／又はその塩を総量で０．００１～１０重量％含む、項１に記載の乳化安定化方法。
項３． 前記水溶性カルボン酸及び／又はその塩の総量１重量部当たり、前記ウフェナマートを１．５重量部以上配合する、項１又は２に記載の乳化安定化方法。
That is, the present invention provides the following aspects.
Item 1. A method for emulsion stabilization, comprising blending ufenamate together with a water-soluble carboxylic acid and/or a salt thereof in an emulsion composition containing the water-soluble carboxylic acid and/or a salt thereof.
Item 2. The method for stabilizing an emulsion according to Item 1, wherein the emulsion composition contains the water-soluble carboxylic acid and/or a salt thereof in a total amount of 0.001 to 10% by weight.
Item 3. The method for emulsion stabilization according to Item 1 or 2, wherein 1.5 parts by weight or more of the ufenamate are blended per 1 part by weight of the total amount of the water-soluble carboxylic acid and/or salt thereof.
本発明によると、水溶性カルボン酸及び／又はその塩を含む乳化組成物に、優れた乳化安定性を備えさせることができる。 According to the present invention, it is possible to provide an emulsion composition containing a water-soluble carboxylic acid and/or its salt with excellent emulsion stability.
本発明の乳化安定化方法は、水溶性カルボン酸及び／又はその塩を含む乳化組成物中に、前記水溶性カルボン酸及び／又はその塩と共に、ウフェナマートを配合することを特徴とする。以下、本発明の乳化安定化方法について詳述する。 The emulsion stabilization method of the present invention is characterized in that ufenamate is blended into an emulsion composition containing a water-soluble carboxylic acid and/or a salt thereof together with the water-soluble carboxylic acid and/or a salt thereof. The emulsion stabilization method of the present invention is described in detail below.
本発明の乳化安定化方法において、乳化安定化とは、保存後において乳化組成物の分離を抑制することをいう。分離とは、乳化組成物から、水相及び／又は油相が分離することをいう。乳化安定化のより好ましい態様としては、保存後において乳化組成物からの水相の分離を抑制することが挙げられ、より好ましい態様としては、保存後において乳化組成物の乳化状態が均一であること、つまりエマルジョン中の液滴が分散媒中に均一に分散した状態が保たれることが挙げられる。 In the emulsion stabilization method of the present invention, emulsion stabilization refers to suppressing separation of the emulsion composition after storage. Separation refers to separation of the aqueous phase and/or oil phase from the emulsion composition. A more preferred aspect of emulsion stabilization is suppressing separation of the aqueous phase from the emulsion composition after storage, and a more preferred aspect is maintaining the emulsion state of the emulsion composition uniform after storage, that is, maintaining a state in which the droplets in the emulsion are uniformly dispersed in the dispersion medium.
水溶性カルボン酸及び／又はその塩
本発明の乳化安定化方法における乳化組成物には、水溶性カルボン酸及び／又はその塩が含まれる。水溶性カルボン酸及び／又はその塩は、水相中でＣＯＯ-基を生じ、ＣＯＯ-基がエマルジョン粒子を不安定化させるが、本発明の乳化安定化方法によって、水溶性カルボン酸及び／又はその塩を含みながらも優れた乳化安定性を備えさせることができる。
Water-soluble carboxylic acid and/or salt thereof The emulsion composition in the emulsion stabilization method of the present invention contains a water-soluble carboxylic acid and/or a salt thereof. The water-soluble carboxylic acid and/or a salt thereof generates a COO 2 -group in the aqueous phase, and the COO 2 -group destabilizes emulsion particles. However, the emulsion stabilization method of the present invention can provide excellent emulsion stability even when the emulsion composition contains a water-soluble carboxylic acid and/or a salt thereof.
水溶性カルボン酸及び／又はその塩としては、美白効果、保湿効果、消炎効果、収斂効果、紫外線吸収効果等が知られている機能性成分を特に制限なく用いることができる。このような機能性成分には、カルボキシル基を有する化合物が数多く知られており、例えば、アスコルビン酸、グリチルリチン酸、コンドロイチン硫酸、クエン酸、グルコン酸、コハク酸、乳酸、リンゴ酸、アミノ酸及びその誘導体、並びにこれらの塩が挙げられる。本発明においては、水溶性カルボン酸及び／又はその塩として、これらの化合物から１種を単独で用いてもよいし、複数種を組み合わせて用いてもよい。 As the water-soluble carboxylic acid and/or its salt, any functional ingredient known to have a whitening effect, a moisturizing effect, an anti-inflammatory effect, an astringent effect, an ultraviolet absorbing effect, etc. can be used without any particular restrictions. Many compounds having a carboxyl group are known as such functional ingredients, and examples of such compounds include ascorbic acid, glycyrrhizic acid, chondroitin sulfate, citric acid, gluconic acid, succinic acid, lactic acid, malic acid, amino acids and their derivatives, and salts thereof. In the present invention, one of these compounds may be used alone as the water-soluble carboxylic acid and/or its salt, or a combination of two or more of them may be used.
アミノ酸としては、グリシン、アラニン、バリン、ロイシン、イソロイシン、セリン、トレオニン、アスパラギン酸、アスパラギン、グルタミン酸、グルタミン、ピロリドンカルボン酸、リシン，アルギニン、メチオニン、フェニルアラニン、チロシン、ヒスチジン、プロリン等が挙げられ、アミノ酸の誘導体としては、グルタミン酸代謝物であるピロリドンカルボン酸等が挙げられる。これらのアミノ酸は、１種を単独で用いてもよいし、複数種を組み合わせて用いてもよい。また、アミノ酸の立体構造については特に限定されず、Ｄ－アミノ酸、Ｌ－アミノ酸、及びＤＬ－アミノ酸のいずれであってもよい。 Examples of amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, pyrrolidone carboxylic acid, lysine, arginine, methionine, phenylalanine, tyrosine, histidine, and proline, and examples of amino acid derivatives include pyrrolidone carboxylic acid, which is a metabolite of glutamic acid. These amino acids may be used alone or in combination. There are no particular limitations on the three-dimensional structure of the amino acids, and they may be any of D-amino acids, L-amino acids, and DL-amino acids.
上記化合物の塩としては、薬学的又は香粧学的に許容されるものである限り特に制限されないが、ナトリウム塩、カリウム塩、リチウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩；マグネシウム塩；亜鉛塩；アンモニウム塩、アルカノールアミン塩等が挙げられる。これらの塩は、１種を単独で用いてもよいし、複数種を組み合わせて用いてもよい。 The salts of the above compounds are not particularly limited as long as they are pharma- ceutically or cosmetically acceptable, and examples thereof include alkali metal salts such as sodium salts, potassium salts, and lithium salts; alkaline earth metal salts such as calcium salts and magnesium salts; magnesium salts; zinc salts; ammonium salts, alkanolamine salts, and the like. These salts may be used alone or in combination.
本発明の乳化安定化方法は、乳化組成物の保存後において優れた乳化安定性を奏するため、乳化組成物に乳化粒子の凝集を引き起こしやすい電解質がより多く共存していても効果的に乳化安定性を得ることができる。このような観点から、本発明の乳化安定化方法における乳化組成物は、水溶性カルボン酸及び／又はその塩の中でも、完全電離によってより多くの電解質を生じる水溶性カルボン酸の塩を含んでいることがより一層好ましい。 The emulsion stabilization method of the present invention provides excellent emulsion stability after storage of the emulsion composition, and therefore can effectively obtain emulsion stability even when the emulsion composition contains a larger amount of electrolytes that tend to cause aggregation of emulsion particles. From this perspective, it is even more preferable that the emulsion composition in the emulsion stabilization method of the present invention contains, among water-soluble carboxylic acids and/or salts thereof, a salt of a water-soluble carboxylic acid that generates a larger amount of electrolytes upon complete ionization.
本発明の乳化安定化方法ににおいて、乳化組成物中の水溶性カルボン酸及び／又はその塩の含有量としては特に限定されず、付与すべき特性に応じて適宜決定することができるが、水溶性カルボン酸及び／又はその塩の総量で、例えば０．００１～１０重量％が挙げられる。より一層好ましい乳化安定性を得る観点から、水溶性カルボン酸及び／又はその塩の含有量の好ましい例として、０．００１～５重量％が挙げられる。また、本発明の乳化安定化方法は、乳化組成物の保存後において優れた乳化安定性を奏するため、乳化組成物に水溶性カルボン酸及び／又はその塩が比較的多く含まれていても、効果的に乳化安定性を奏することができる。このような観点から、本発明の乳化安定化方法においては、乳化組成物中の水溶性カルボン酸及び／又はその塩の含有量の好適な例として、０．１～１０重量％、好ましくは１～１０重量％、より好ましくは２～１０重量％が挙げられる。 In the emulsion stabilization method of the present invention, the content of the water-soluble carboxylic acid and/or its salt in the emulsion composition is not particularly limited and can be appropriately determined depending on the properties to be imparted, but the total amount of the water-soluble carboxylic acid and/or its salt is, for example, 0.001 to 10% by weight. From the viewpoint of obtaining even more favorable emulsion stability, a preferred example of the content of the water-soluble carboxylic acid and/or its salt is 0.001 to 5% by weight. In addition, since the emulsion stabilization method of the present invention exhibits excellent emulsion stability after storage of the emulsion composition, even if the emulsion composition contains a relatively large amount of water-soluble carboxylic acid and/or its salt, it can effectively exhibit emulsion stability. From this viewpoint, in the emulsion stabilization method of the present invention, a preferred example of the content of the water-soluble carboxylic acid and/or its salt in the emulsion composition is 0.1 to 10% by weight, preferably 1 to 10% by weight, more preferably 2 to 10% by weight.
ウフェナマート
本発明の乳化安定化方法において、乳化組成物に含まれるウフェナマートは、フルフェナム酸ブチルとも称され、水難溶性の非ステロイド性抗炎症薬として公知の成分である。水溶性カルボン酸及び／又はその塩を含む乳化組成物は保存後における性状が不安定であるが、本発明の乳化安定化方法における乳化組成物は、ウフェナマートを配合することで、優れた乳化安定性を奏する。このような本発明の効果が得られるメカニズムとしては定かではないが、ウフェナマートが有するトリフルオロメチル基の極めて高い疎水性が、界面活性剤が油相へ過度に分配されることを妨げることで界面構造を安定化し、これによってＣＯＯ-基によるエマルジョン粒子の不安定化が抑制されるものと考えられる。
Ufenamate In the emulsion stabilization method of the present invention, ufenamate contained in the emulsion composition is also called butyl flufenamate, and is a known component as a poorly water-soluble nonsteroidal anti-inflammatory drug. Although the emulsion composition containing water-soluble carboxylic acid and/or its salt has unstable properties after storage, the emulsion composition in the emulsion stabilization method of the present invention exhibits excellent emulsion stability by blending ufenamate. Although the mechanism by which the effect of the present invention is obtained is not clear, it is considered that the extremely high hydrophobicity of the trifluoromethyl group of ufenamate prevents the surfactant from being excessively distributed into the oil phase, thereby stabilizing the interface structure, thereby suppressing the destabilization of emulsion particles caused by COO- groups.
本発明の乳化安定化方法において、乳化組成物におけるウフェナマートの含有量については特に限定されず、奏すべき乳化安定性に応じて適宜設定されるが、例えば１～２０重量％、好ましくは２～１０重量％、更に好ましくは３～７重量％が挙げられる。 In the emulsion stabilization method of the present invention, the content of ufenamate in the emulsion composition is not particularly limited and is appropriately set depending on the emulsion stability to be achieved, but may be, for example, 1 to 20% by weight, preferably 2 to 10% by weight, and more preferably 3 to 7% by weight.
本発明の乳化安定化方法において、水溶性カルボン酸及び／又はその塩に対するウフェナマートの比率については、上記の各成分の各含有量に応じて定まるが、より一層優れた乳化安定性を得る観点から、例えば、水溶性カルボン酸及び／又はその塩の総量１重量部当たりのウフェナマートの含有量として、例えば１．５重量部以上、好ましくは１．８重量部以上、より好ましくは２重量部以上が挙げられる。水溶性カルボン酸及び／又はその塩の総量１重量部当たりのウフェナマートの含有量の範囲の上限としては特に限定されないが、例えば４０重量部以下、好ましくは２０重量部以下、より好ましくは１０重量部以下、更に好ましくは５重量部以下が挙げられる。 In the emulsion stabilization method of the present invention, the ratio of ufenamate to the water-soluble carboxylic acid and/or its salt is determined according to the content of each of the above-mentioned components, but from the viewpoint of obtaining even better emulsion stability, the content of ufenamate per part by weight of the total amount of water-soluble carboxylic acid and/or its salt is, for example, 1.5 parts by weight or more, preferably 1.8 parts by weight or more, and more preferably 2 parts by weight or more. The upper limit of the range of the content of ufenamate per part by weight of the total amount of water-soluble carboxylic acid and/or its salt is not particularly limited, but may be, for example, 40 parts by weight or less, preferably 20 parts by weight or less, more preferably 10 parts by weight or less, and even more preferably 5 parts by weight or less.
油分
本発明の乳化安定化方法において、乳化組成物は、油相の基剤成分として油分を含む。油分としては薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、液状油、固形油、高級アルコール等が挙げられる。これらの油分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
In the emulsion stabilization method of the present invention, the emulsion composition contains an oil as a base component of the oil phase. The oil is not particularly limited as long as it is pharma- ceutical or cosmetically acceptable, and examples of the oil include liquid oil, solid oil, and higher alcohol. These oils may be used alone or in combination of two or more.
本発明の乳化安定化方法において、乳化組成物における油分の含有量については、乳化組成物の乳化タイプ、形態、用途等に応じて適宜設定すればよいが、例えば、２～６０重量％、好ましくは４～３０重量％、より好ましくは４～１５重量％、さらに好ましくは６～８重量％が挙げられる。 In the emulsion stabilization method of the present invention, the oil content in the emulsion composition may be appropriately set depending on the emulsion type, form, and application of the emulsion composition, and may be, for example, 2 to 60% by weight, preferably 4 to 30% by weight, more preferably 4 to 15% by weight, and even more preferably 6 to 8% by weight.
本発明の乳化安定化方法において、乳化組成物には、上記の油分の中でも、液状油を含有することが好ましい。液状油とは、２５℃において液状の形態を保つ油である。液状油としては、化粧料や外用医薬品等に通常用いられるものであればよく、例えば、；オレイン酸、インステアリン酸等の脂肪酸；エチルヘキサン酸セチル、パルミチン酸エチルヘキシル、ミリスチン酸オクチルドデシル、ミリスチン酸イソプロピル、ジエチルヘキサン酸ネオペンチルグリコール、トリ２－エチルへキサン酸グリセリル、オレイン酸オクチルドデシル、ミリスチン酸イソプロピル、トリイソステアリン酸グリセリル、ジバラメトキシケイヒ酸－モノエチルへキサン酸グリセリル等のエステル油；ジメチルポリシロキサン、メチルハイドロジエンポリシロキサン、メチルフェニルポリシロキサン、オクタメチルシクロテトラシロキサン等のシリコーン油；流動パラフィン、スクワレン、スクワラン等の液状炭化水素油等が挙げられる。 In the emulsion stabilization method of the present invention, it is preferable that the emulsion composition contains a liquid oil among the above oils. A liquid oil is an oil that maintains a liquid form at 25°C. The liquid oil may be any oil that is commonly used in cosmetics and topical medicines, and examples of such oils include fatty acids such as oleic acid and isostearic acid; ester oils such as cetyl ethylhexanoate, ethylhexyl palmitate, octyldodecyl myristate, isopropyl myristate, neopentyl glycol diethylhexanoate, glyceryl tri-2-ethylhexanoate, octyldodecyl oleate, isopropyl myristate, glyceryl triisostearate, and glyceryl di-methylmethoxycinnamate-monoethylhexanoate; silicone oils such as dimethylpolysiloxane, methylhydrogenpolysiloxane, methylphenylpolysiloxane, and octamethylcyclotetrasiloxane; and liquid hydrocarbon oils such as liquid paraffin, squalene, and squalane.
これらの液状油は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These liquid oils may be used alone or in combination of two or more.
これらの液状油の中でも、好ましくは、エステル油、シリコーン油、液状炭化水素油が挙げられ、より好ましくはミリスチン酸オクチルドデシル、ミリスチン酸イソプロピル、ジメチルポリシロキサン、流動パラフィンが挙げられる。また、これらの液状油の中でも、より一層好ましい乳化安定性を得る観点から、好ましくは液状炭化水素油が挙げられ、より好ましくは流動パラフィンが挙げられる。 Among these liquid oils, preferably, ester oil, silicone oil, and liquid hydrocarbon oil are used, and more preferably, octyldodecyl myristate, isopropyl myristate, dimethylpolysiloxane, and liquid paraffin are used. Furthermore, among these liquid oils, from the viewpoint of obtaining even more preferable emulsion stability, preferably, liquid hydrocarbon oil is used, and more preferably, liquid paraffin is used.
本発明の乳化安定化方法において、乳化安定化剤に液状油を含有させる場合、その含有量については、特に制限されず、乳化組成物の乳化タイプ、形態、用途等に応じて適宜設定すればよいが、例えば、０．５～３０重量％、好ましくは１～２０重量％、より好ましくは３～１０重量％、さらに好ましくは５～８重量％が挙げられる。 In the emulsion stabilization method of the present invention, when the emulsion stabilizer contains a liquid oil, the content is not particularly limited and may be appropriately set depending on the emulsion type, form, and application of the emulsion composition, but may be, for example, 0.5 to 30% by weight, preferably 1 to 20% by weight, more preferably 3 to 10% by weight, and even more preferably 5 to 8% by weight.
水
本発明の乳化安定化方法において、乳化組成物は、水相の基剤成分として水を含む。本発明の乳化組成物における水の含有量について、乳化組成物の乳化タイプ、形態、用途等に応じて適宜設定すればよいが、例えば、３０～９５重量％、好ましくは３０～９０重量％、より好ましくは３０～８０重量％、更に好ましくは３０～７５重量％が挙げられる。
In the emulsion stabilization method of the present invention, the emulsion composition contains water as a base component of the aqueous phase. The content of water in the emulsion composition of the present invention may be appropriately set depending on the emulsion type, form, application, etc. of the emulsion composition, and may be, for example, 30 to 95% by weight, preferably 30 to 90% by weight, more preferably 30 to 80% by weight, and even more preferably 30 to 75% by weight.
また、本発明の乳化安定化方法は、乳化組成物に、保存後の水相分離を抑制する優れた乳化安定性を付与することができるため、乳化組成物が、本来的に水相分離がより一層生じやすい、水を多く含む場合であっても、優れた乳化安定性を奏することが可能になる。このような本発明の効果を鑑みれば、本発明の乳化安定化方法における乳化組成物の好適な態様として、水の含有量が比較的多い乳化組成物が挙げられる。より具体的には、本発明の乳化安定化方法における乳化組成物中の水の含有量の好適な例として、例えば、４０～９５重量％、好ましくは４５～９５重量％、より好ましくは５０～９５重量％、さらに好ましくは５５～９５重量％、一層好ましくは６０～９５重量％が挙げられる。 The emulsion stabilization method of the present invention can impart excellent emulsion stability to the emulsion composition, suppressing aqueous phase separation after storage, and therefore can provide excellent emulsion stability even when the emulsion composition contains a large amount of water, which is inherently more prone to aqueous phase separation. In view of the effects of the present invention, a suitable embodiment of the emulsion composition in the emulsion stabilization method of the present invention is an emulsion composition having a relatively high water content. More specifically, suitable examples of the water content in the emulsion composition in the emulsion stabilization method of the present invention include, for example, 40 to 95% by weight, preferably 45 to 95% by weight, more preferably 50 to 95% by weight, even more preferably 55 to 95% by weight, and even more preferably 60 to 95% by weight.
界面活性剤
本発明の乳化安定化方法において、乳化組成物は、油相及び水相を乳化させる成分として界面活性剤を含む。界面活性剤としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、ノニオン性界面活性剤、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤等が挙げられる。
In the emulsion stabilization method of the present invention, the emulsion composition contains a surfactant as a component that emulsifies the oil phase and the aqueous phase. The surfactant is not particularly limited as long as it is medicamentally or cosmetically acceptable, and examples thereof include nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, etc.
界面活性剤のＨＬＢ値としては、より一層優れた乳化安定性を得る観点から、例えば１０～１９、好ましくは１３～１７．５、より好ましくは１３．５～１５．５が挙げられる。ＨＬＢ値は、川上法（ＨＬＢ値=７＋１１．７ｌｏｇ(親水部の式量の総和/親油部の式量の総和)）に従って算出される値である。 From the viewpoint of obtaining even better emulsion stability, the HLB value of the surfactant may be, for example, 10 to 19, preferably 13 to 17.5, and more preferably 13.5 to 15.5. The HLB value is a value calculated according to the Kawakami method (HLB value = 7 + 11.7 log (sum of formula weights of hydrophilic parts/sum of formula weights of lipophilic parts)).
これらの界面活性剤の中でも、より優れた乳化安定性を得る観点から、好ましくはノニオン性界面活性剤が挙げられる。 Among these surfactants, nonionic surfactants are preferred from the viewpoint of obtaining better emulsion stability.
ノニオン性界面活性剤としては、具体的には、ポリオキシエチレン硬化ヒマシ油類（例えば、ＰＥＧ－４０水添ヒマシ油、ＰＥＧ－５０水添ヒマシ油、ＰＥＧ－６０水添ヒマシ油、ＰＥＧ－８０水添ヒマシ油、ＰＥＧ－１００水添ヒマシ油、）；ソルビタン脂肪酸エステル類（例えば、ソルビタンモノオレエート、ソルビタンモノイソステアレート、ソルビタンモノラウレート、ソルビタンモノパルミテート、ソルビタンモノステアレート、ソルビタンセスキオレエート、ソルビタントリオレエート、ペンタ－２－エチルヘキシル酸ジグリセロールソルビタン、テトラ－２－エチルヘキシル酸ジグリセロールソルビタン等）；グリセリン脂肪酸エステル類（例えば、モノ綿実油脂肪酸グリセリル、モノエルカ酸グリセリル、セスキオレイン酸グリセリル、モノステアリン酸グリセリル（ステアリン酸グリセリン）、α，α’－オレイン酸ピログルタミン酸グリセリル、モノステアリン酸グリセリンリンゴ酸等）；プロピレングリコール脂肪酸エステル類（例えば、モノステアリン酸プロピレングリコール等）；グリセリンアルキルエーテル；ステアレス－２；ポリオキシエチレンソルビタン脂肪酸エステル類（例えば、ポリオキシエチレンソルビタンモノオレエート、ポリオキシエチレンソルビタンモノステアレート、ポリオキシエチレンソルビタンテトラオレエート等）；ポリオキシエチレンソルビット脂肪酸エステル類（例えば、ポリオキシエチレンソルビットモノラウレート、ポリオキシエチレンソルビットモノオレエート、ポリオキシエチレンソルビットペンタオレエート、ポリオキシエチレンソルビットモノステアレート等）；ポリオキシエチレングリセリン脂肪酸エステル類（例えば、ポリオキシエチレングリセリンモノステアレート、ポリオキシエチレングリセリンモノイソステアレート、ポリオキシエチレングリセリントリイソステアレート等）；ポリオキシエチレン脂肪酸エステル類（例えば、ポリオキシエチレンモノオレエート、ポリオキシエチレンモノステアレート、ポリオキシエチレンジステアレート、ポリオキシエチレンモノジオレエート、ジステアリン酸エチレングリコール等）；ポリオキシエチレンアルキルエーテル類（例えば、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンオレイルエーテル、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンベヘニルエーテル、ポリオキシエチレン２－オクチルドデシルエーテル、ポリオキシエチレンコレスタノールエーテル等）；プルロニック型類（例えば、プルロニック等）；ポリオキシエチレン・ポリオキシプロピレンアルキルエーテル類（例えば、ポリオキシエチレン・ポリオキシプロピレン－セチルエーテル、ポリオキシエチレン・ポリオキシプロピレン－２－デシルテトラデシルエーテル、ポリオキシエチレン・ポリオキシプロピレンモノブチルエーテル、ポリオキシエチレン・ポリオキシプロピレン水添ラノリン、ポリオキシエチレン・ポリオキシプロピレングリセリンエーテル等）；ステアレス－２１等が挙げられる。 Specific examples of nonionic surfactants include polyoxyethylene hydrogenated castor oils (e.g., PEG-40 hydrogenated castor oil, PEG-50 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-80 hydrogenated castor oil, PEG-100 hydrogenated castor oil); sorbitan fatty acid esters (e.g., sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexyl acid, diglycerol sorbitan tetra-2-ethylhexyl acid, etc.); glycerin fatty acid esters (e.g., monoglyceryl cottonseed oil fatty acid, monoerucic acid, etc.); glyceryl, glyceryl sesquioleate, glyceryl monostearate (glycerin stearate), α,α'-oleic acid pyroglutamate glyceryl, monostearate glycerin malate, etc.); propylene glycol fatty acid esters (e.g., propylene glycol monostearate, etc.); glycerin alkyl ether; steareth-2; polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tetraoleate, etc.); polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan mono oleate, polyoxyethylene sorbitol pentaoleate, polyoxyethylene sorbitol monostearate, etc.); polyoxyethylene glycerin fatty acid esters (e.g., polyoxyethylene glycerin monostearate, polyoxyethylene glycerin monoisostearate, polyoxyethylene glycerin triisostearate, etc.); polyoxyethylene fatty acid esters (e.g., polyoxyethylene monooleate, polyoxyethylene monostearate, polyoxyethylene distearate, polyoxyethylene monodioleate, ethylene glycol distearate, etc.); polyoxyethylene alkyl ethers (e.g., polyoxyethylene lauryl ether, polyoxyethylene oleate, yl ether, polyoxyethylene stearyl ether, polyoxyethylene behenyl ether, polyoxyethylene 2-octyldodecyl ether, polyoxyethylene cholestanol ether, etc.); Pluronic types (e.g., Pluronic, etc.); polyoxyethylene-polyoxypropylene alkyl ethers (e.g., polyoxyethylene-polyoxypropylene-cetyl ether, polyoxyethylene-polyoxypropylene-2-decyltetradecyl ether, polyoxyethylene-polyoxypropylene monobutyl ether, polyoxyethylene-polyoxypropylene hydrogenated lanolin, polyoxyethylene-polyoxypropylene glycerin ether, etc.); steareth-21, etc.
これらの界面活性剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These surfactants may be used alone or in combination of two or more.
これらのノニオン性界面活性剤の中でも、より優れた乳化安定性を得る観点から、好ましくはポリオキシエチレン硬化ヒマシ油類、ポリオキシエチレンソルビタン脂肪酸エステル類、ポリオキシエチレン脂肪酸エステル類が挙げられ、より好ましくは、ＰＥＧ－６０水添ヒマシ油、ポリオキシエチレンソルビタンモノステアレート、ポリオキシエチレンモノステアレートが挙げられる。また、これらのノニオン性界面活性剤の中でも、より一層優れた乳化安定性を得る観点から、ポリオキシエチレンソルビタン脂肪酸エステル類が挙げられ、より好ましくは、ポリオキシエチレンソルビタンモノステアレートが挙げられる。 Among these nonionic surfactants, from the viewpoint of obtaining better emulsion stability, polyoxyethylene hydrogenated castor oils, polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene fatty acid esters are preferred, and more preferred are PEG-60 hydrogenated castor oil, polyoxyethylene sorbitan monostearate, and polyoxyethylene monostearate. Furthermore, among these nonionic surfactants, from the viewpoint of obtaining even better emulsion stability, polyoxyethylene sorbitan fatty acid esters are preferred, and more preferred is polyoxyethylene sorbitan monostearate.
本発明の乳化安定化方法において、乳化組成物中の界面活性剤の含有量については、使用する界面活性剤の種類等に応じて適宜設定すればよいが、例えば０．５～７重量％、好ましくは１～５重量％、より好ましくは２～５重量％、更に好ましくは３～５重量％が挙げられる。 In the emulsion stabilization method of the present invention, the content of the surfactant in the emulsion composition may be appropriately set depending on the type of surfactant used, etc., but may be, for example, 0.5 to 7% by weight, preferably 1 to 5% by weight, more preferably 2 to 5% by weight, and even more preferably 3 to 5% by weight.
その他の成分
本発明の乳化安定化方法において、乳化組成物は、前述する成分の他に、必要に応じて、通常使用される他の添加剤が含まれていてもよい。このような添加剤としては、例えば、多価アルコール、増粘剤、ｐＨ調節剤、緩衝剤、可溶化剤、キレート剤、防腐剤、保存剤、酸化防止剤、安定化剤、香料、着色料等が挙げられる。
In the emulsion stabilization method of the present invention, the emulsion composition may contain, in addition to the above-mentioned components, other commonly used additives as necessary. Examples of such additives include polyhydric alcohols, thickeners, pH regulators, buffers, solubilizers, chelating agents, preservatives, antioxidants, stabilizers, fragrances, colorants, etc.
多価アルコールとしては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、プロピレングリコール、１，３－ブチレングリコール、エチレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール等の２価アルコール；グリセリン等の３価アルコール、マクロゴール４０００、マクロゴール６０００等のポリエチレングリコール等が挙げられる。これらの多価アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。これらの多価アルコールの中でも、より優れた乳化安定性を得る観点から、好ましくは２価アルコール、３価アルコールが挙げられ、より好ましくは１，３－ブチレングリコール、グリセリンが挙げられる。 The polyhydric alcohol is not particularly limited as long as it is pharma- ceutically or cosmetically acceptable, and examples thereof include dihydric alcohols such as propylene glycol, 1,3-butylene glycol, ethylene glycol, isoprene glycol, diethylene glycol, and dipropylene glycol; trihydric alcohols such as glycerin; and polyethylene glycols such as Macrogol 4000 and Macrogol 6000. These polyhydric alcohols may be used alone or in combination of two or more. Among these polyhydric alcohols, from the viewpoint of obtaining better emulsion stability, dihydric alcohols and trihydric alcohols are preferred, and 1,3-butylene glycol and glycerin are more preferred.
本発明の乳化安定化方法において、乳化組成物中に多価アルコールを含有させる場合、その含有量については、使用する多価アルコールの種類等に応じて適宜設定すればよいが、例えば１～２０重量％、好ましくは５～１８重量％、より好ましくは１０～１６重量％が挙げられる。 When a polyhydric alcohol is contained in the emulsion composition in the emulsion stabilization method of the present invention, the content may be appropriately set depending on the type of polyhydric alcohol used, and may be, for example, 1 to 20% by weight, preferably 5 to 18% by weight, and more preferably 10 to 16% by weight.
増粘剤としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、カルボキシビニルポリマー、ヒプロメロース、ポリビニルピロリドン、アルギン酸ナトリウム、エチルセルロース、カルボキシメチルセルロースナトリウム、キサンタンガム、カラギーナン等が挙げられる。これらの増粘剤の中でも、より優れた乳化安定性を得る観点から、好ましくはキサンタンガムが挙げられる。また、これらの増粘剤のうち、カルボキシビニルポリマーは、水溶性カルボン酸及び／又はその塩との共存下で極端な粘度低下を受けるため、水溶性カルボン酸及び／又はその塩を含む通常の乳化組成物に配合すると保存安定性の顕著な低下を招来するが、本発明の乳化安定化方法は、乳化組成物に保存後における優れた乳化安定性を付与することができるため、カルボキシビニルポリマーが含まれていても効果的に乳化安定性を奏することができる。このような本発明の効果に鑑みれば、本発明の乳化安定化方法における乳化組成物には増粘剤として少なくともカルボキシビニルポリマーを含んでいることが好ましい。 The thickener is not particularly limited as long as it is pharma- ceutically or cosmetically acceptable, and examples thereof include carboxyvinyl polymer, hypromellose, polyvinylpyrrolidone, sodium alginate, ethyl cellulose, sodium carboxymethylcellulose, xanthan gum, carrageenan, and the like. Among these thickeners, xanthan gum is preferred from the viewpoint of obtaining better emulsion stability. Among these thickeners, carboxyvinyl polymer undergoes an extreme viscosity reduction in the presence of water-soluble carboxylic acid and/or its salt, and therefore, when incorporated into a normal emulsion composition containing water-soluble carboxylic acid and/or its salt, it leads to a significant reduction in storage stability. However, the emulsion stabilization method of the present invention can impart excellent emulsion stability after storage to the emulsion composition, and therefore, even if the emulsion contains carboxyvinyl polymer, it can effectively achieve emulsion stability. In view of such effects of the present invention, it is preferable that the emulsion composition in the emulsion stabilization method of the present invention contains at least carboxyvinyl polymer as a thickener.
本発明の乳化安定化方法において、乳化組成物に増粘剤を含有させる場合、その含有量については、使用する増粘剤の種類等に応じて適宜設定すればよいが、より優れた乳化安定性を得る観点から、例えば０．１～２重量％、好ましくは０．１～１．８重量％、より好ましくは０．２～１．５重量％、更に好ましくは０．３～１重量％、一層好ましくは０．３～０．６重量％が挙げられる。また、本発明の乳化安定化方法において、乳化組成物にカルボキシビニルポリマーを含有させる場合、カルボキシビニルポリマーの含有量としては、例えば０．１～１重量％、好ましくは０．３～０．５重量％、より好ましくは０．３５～０．４５重量％が挙げられる。また、水溶性カルボン酸及び／又はその塩に対するカルボキシビニルポリマーの比率については、上記の各成分の各含有量に応じて定まるが、例えば、水溶性カルボン酸及び／又はその塩の総量１重量部当たりのカルボキシビニルポリマーの含有量として、例えば０．０１～０．５重量部、好ましくは０．０３～０．３重量部、より好ましくは０．０６～０．２重量部が挙げられる。 In the emulsion stabilization method of the present invention, when a thickener is contained in the emulsion composition, the content of the thickener may be appropriately set depending on the type of thickener used, but from the viewpoint of obtaining better emulsion stability, the content is, for example, 0.1 to 2% by weight, preferably 0.1 to 1.8% by weight, more preferably 0.2 to 1.5% by weight, even more preferably 0.3 to 1% by weight, and even more preferably 0.3 to 0.6% by weight. In the emulsion stabilization method of the present invention, when a carboxyvinyl polymer is contained in the emulsion composition, the content of the carboxyvinyl polymer is, for example, 0.1 to 1% by weight, preferably 0.3 to 0.5% by weight, and more preferably 0.35 to 0.45% by weight. The ratio of the carboxyvinyl polymer to the water-soluble carboxylic acid and/or its salt is determined according to the content of each of the above components, but for example, the content of the carboxyvinyl polymer per 1 part by weight of the total amount of the water-soluble carboxylic acid and/or its salt is, for example, 0.01 to 0.5 parts by weight, preferably 0.03 to 0.3 parts by weight, and more preferably 0.06 to 0.2 parts by weight.
更に、本発明の乳化安定化方法において、乳化組成物は、前述する成分の他に、薬学的又は香粧学的な生理機能を発揮できる薬効成分が、必要に応じて含まれていてもよい。このような薬効成分としては、例えば、ステロイド剤（デキサメタゾン、塩酸デキサメタゾン、酢酸デキサメタゾン、塩酸ヒドロコルチゾン、吉草酸プレドニゾロン、酢酸プレドニゾロン等）、抗ヒスタミン剤（ジフェンヒドラミン、塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン等）、局所麻酔剤（リドカイン、ジブカイン、プロカイン、テトラカイン、ブピバカイン、メピバカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩）、安息香酸アルキルエステル（例えばアミノ安息香酸エチル、塩酸パラブチルアミノ安息香酸ジエチルアミノエチル）、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等）、抗炎症剤（アラントイン、サリチル酸、サリチル酸グリコール、サリチル酸メチル、インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等）、殺菌剤（塩化ベンザルコニウム、塩化デカリニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、塩酸クロルヘキシジン、グルコン酸クロルヘキシジン、アンモニア水、スルファジアジン、乳酸、フェノール等）、鎮痒剤（クロタミトン、チアントール等）、皮膚保護剤（コロジオン、ヒマシ油等）、血行促進成分（ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等）、ビタミン類（ビタミンＡ，Ｂ，Ｃ，Ｄ，Ｅ等）、ムコ多糖類（コンドロイチン硫酸ナトリウム、グルコサミン、ヒアルロン酸等）等が挙げられる。これらの薬効成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、本発明の乳化安定化方法において、乳化組成物にこれらの薬効成分を含有させる場合、その含有量については、使用する薬効成分の種類、期待する効果等に応じて適宜設定すればよい。 Furthermore, in the emulsion stabilization method of the present invention, the emulsion composition may contain, in addition to the components described above, medicinal ingredients capable of exerting pharmaceutical or cosmetic physiological functions, as necessary. Examples of such medicinal ingredients include steroids (dexamethasone, dexamethasone hydrochloride, dexamethasone acetate, hydrocortisone hydrochloride, prednisolone valerate, prednisolone acetate, etc.), antihistamines (diphenhydramine, diphenhydramine hydrochloride, chlorpheniramine maleate, etc.), local anesthetics (lidocaine, dibucaine, procaine, tetracaine, bupivacaine, mepivacaine, chloroprocaine, proparacaine, meprylcaine, or salts thereof), alkyl benzoates (e.g., ethyl aminobenzoate, diethylaminoethyl p-butylaminobenzoate hydrochloride), orthocaine, oxethazaine, oxypolyethyleneoxydecane, scopolamine extract, percaminepase, tesit decitin, etc.), anti-inflammatory agents (arabinose, anthoin, salicylic acid, glycol salicylate, methyl salicylate, indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), bactericides (benzalkonium chloride, dequalinium chloride, benzethonium chloride, cetylpyridinium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, aqueous ammonia, sulfadiazine, lactic acid, phenol, etc.), antipruritic agents (crotamiton, thianthol, etc.), skin protectants (collodion, castor oil, etc.), blood circulation promoting components (vanillylamide nonylate, benzyl nicotinate, capsaicin, chili pepper extract, etc.), vitamins (vitamins A, B, C, D, E, etc.), mucopolysaccharides (sodium chondroitin sulfate, glucosamine, hyaluronic acid, etc.), etc. These medicinal components may be used alone or in combination of two or more. Furthermore, in the emulsion stabilization method of the present invention, when these medicinal ingredients are contained in the emulsion composition, the content may be appropriately set depending on the type of medicinal ingredient used, the expected effect, etc.
製剤形態・用途
本発明の乳化安定化方法において、乳化組成物の乳化タイプは、油中水型又は水中油型のいずれであってもよい。本発明の乳化安定化方法は、乳化組成物に、保存後における分離を抑制する優れた乳化安定性を備えさせることができるため、本来的に水相分離がより一層生じやすい、水中油型のような水を多く含む乳化組成物に対しても、優れた乳化安定性を備えさせることが可能になる。このような本発明の効果に鑑みれば、本発明の乳化安定化方法における乳化組成物の好ましい乳化タイプは、水の含有量が比較的多い水中油型である。
Formulation and Use In the emulsion stabilization method of the present invention, the emulsion type of the emulsion composition may be either water-in-oil type or oil-in-water type. The emulsion stabilization method of the present invention can provide the emulsion composition with excellent emulsion stability that suppresses separation after storage, so that it is possible to provide excellent emulsion stability even for emulsion compositions that contain a lot of water, such as oil-in-water type, which is inherently more prone to aqueous phase separation. In view of the effects of the present invention, the preferred emulsion type of the emulsion composition in the emulsion stabilization method of the present invention is oil-in-water type, which has a relatively high water content.
本発明の乳化安定化方法において、乳化組成物は、化粧料、外用医薬部外品、外用医薬品等の外用剤として使用することができる。本発明の乳化安定化方法におけり乳化組成物の製品形態については、特に制限されないが、例えば、クリーム剤、軟膏剤、乳液剤、ゲル剤、油剤、ローション剤、リニメント剤、エアゾール剤等が挙げられる。これらの中でも、好ましくは、クリーム剤、軟膏剤、乳液剤、ローション剤が挙げられ、より好ましくは、クリーム剤、乳液剤、ローション剤が挙げられる。 In the emulsion stabilization method of the present invention, the emulsion composition can be used as an external preparation such as a cosmetic, an external quasi-drug, or an external medicine. The product form of the emulsion composition in the emulsion stabilization method of the present invention is not particularly limited, and examples thereof include creams, ointments, emulsions, gels, oils, lotions, liniments, and aerosols. Of these, creams, ointments, emulsions, and lotions are preferred, and creams, emulsions, and lotions are more preferred.
製造方法
本発明の乳化安定化方法において、乳化組成物は、乳化タイプに応じて、公知の乳化製剤の製剤化手法に従って製造することができる。例えば、本発明の乳化安定化方法における乳化組成物の製造方法としては、含有させる成分を水溶性成分と油性成分に分けて、水溶性成分を含む水相と、油性成分を含む油相とを調製し、これらを公知の手法に従って乳化させる方法が挙げられる。
In the emulsion stabilization method of the present invention, the emulsion composition can be manufactured according to the formulation method of known emulsion preparations depending on the emulsion type.For example, the method of manufacturing the emulsion composition in the emulsion stabilization method of the present invention includes a method of dividing the components to be contained into water-soluble components and oily components, preparing an aqueous phase containing the water-soluble components and an oily phase containing the oily components, and emulsifying them according to a known method.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these.
試験例
表１及び２に示すに示す乳化組成物を調製した。具体的には、（Ｂ）成分を（I）の各成分の混合物に加え、７０～８０℃で溶解させ、油相を調製した。一方、（II）の各成分の混合物を７５～８５℃で溶解させ、更に（Ａ）成分の５０重量％水溶液を加え、水相を調製した。７０～８０℃に加温した油相に、７０～８０℃に加温した水相を加え、ホモミキサーを用いて撹拌して乳化し、３５℃まで冷却した。これによって、乳化組成物（乳液剤；水中油型）を製造した。
Test Examples The emulsion compositions shown in Tables 1 and 2 were prepared. Specifically, component (B) was added to a mixture of each component (I) and dissolved at 70 to 80°C to prepare an oil phase. Meanwhile, a mixture of each component (II) was dissolved at 75 to 85°C, and a 50% by weight aqueous solution of component (A) was added to prepare an aqueous phase. A water phase heated to 70 to 80°C was added to an oil phase heated to 70 to 80°C, emulsified by stirring using a homomixer, and cooled to 35°C. In this way, an emulsion composition (emulsion; oil-in-water type) was produced.
得られた各乳化組成物１０ｇを、１５ｍＬの透明プラスチックチューブに充填し、密封して、遠心分離機により３，０００ｒｐｍで１０分遠心した。遠心後の各乳化組成物を目視にて観察し、以下の基準に基づいて乳化安定性を評価した。結果を表１及び２に示す。
－－：相分離が明確に認められ、水相の濁りの程度が少ない。
－：相分離が明確に認められ、水相の濁りの程度が大きい。
＋：相分離が認められず、クリーミング傾向のみ認められる。
＋＋：相分離が認められず、チューブの底先端部にのみ僅かなクリーミング傾向が認められる。
＋＋＋：相分離が認められず、乳化状態も均一である。
なお、クリーミング傾向とは、乳化状態の不均一状態をいい、具体的には、生成したエマルジョン中の液滴が、分散媒との比重差によって浮上又は沈降する過程にある状態をいう。
10 g of each of the obtained emulsion compositions was filled into a 15 mL transparent plastic tube, sealed, and centrifuged at 3,000 rpm for 10 minutes using a centrifuge. After centrifugation, each emulsion composition was visually observed and evaluated for emulsion stability based on the following criteria. The results are shown in Tables 1 and 2.
--: Phase separation was clearly observed, and the degree of turbidity of the aqueous phase was low.
-: Phase separation was clearly observed, and the water phase was significantly turbid.
+: No phase separation was observed, and only a creaming tendency was observed.
++: No phase separation observed, slight creaming tendency observed only at the bottom tip of the tube.
+++: No phase separation was observed and the emulsion was uniform.
The creaming tendency refers to a non-uniform emulsified state, specifically, a state in which droplets in the generated emulsion are in the process of floating up or sinking down due to the difference in specific gravity with the dispersion medium.
表２から明らかなように、ピロリドンカルボン酸ナトリウムを含まない乳化組成物では乳化状態は安定である（参考例）が、ピロリドンカルボン酸ナトリウムを含む乳化組成物では乳化状態が不安定になる（比較例１、２）ことが認められた。これに対し、表１から明らかなように、ピロリドンカルボン酸ナトリウムを含む乳化組成物に更にウフェナマートを配合することで、乳化状態が安定化した（実施例１～７）。この乳化安定性の向上効果は、特に、実施例１、４～７において顕著であった。 As is clear from Table 2, the emulsion state was stable in the emulsion composition not containing sodium pyrrolidone carboxylate (Reference Example), but the emulsion state was found to be unstable in the emulsion composition containing sodium pyrrolidone carboxylate (Comparative Examples 1 and 2). In contrast, as is clear from Table 1, the emulsion state was stabilized by further blending ufenamate with the emulsion composition containing sodium pyrrolidone carboxylate (Examples 1 to 7). This effect of improving emulsion stability was particularly noticeable in Examples 1 and 4 to 7.
処方例
表３及び４に示す処方の乳化組成物（水中油型）を調製した。いずれの乳化組成物も、ウフェナマートによって優れた乳化安定性を獲得した。
Formulation Examples Emulsion compositions (oil-in-water type) were prepared according to the formulations shown in Tables 3 and 4. All of the emulsion compositions achieved excellent emulsion stability due to the ufenamate.
Claims (3)
3. The method for emulsion stabilization according to claim 1, wherein 1.5 parts by weight or more of said ufenamate are blended per 1 part by weight of the total amount of said pyrrolidone carboxylic acid and/or its salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019221140A JP7570174B2 (en) | 2019-12-06 | 2019-12-06 | Emulsion stabilization method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019221140A JP7570174B2 (en) | 2019-12-06 | 2019-12-06 | Emulsion stabilization method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021091610A JP2021091610A (en) | 2021-06-17 |
| JP7570174B2 true JP7570174B2 (en) | 2024-10-21 |
Family
ID=76311758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221140A Active JP7570174B2 (en) | 2019-12-06 | 2019-12-06 | Emulsion stabilization method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7570174B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024114984A (en) * | 2019-12-06 | 2024-08-23 | 小林製薬株式会社 | Emulsion composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7854163B2 (en) * | 2021-08-31 | 2026-05-01 | 株式会社日本色材工業研究所 | Water-in-oil emulsion cosmetic |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010270029A (en) | 2009-05-20 | 2010-12-02 | Shiseido Co Ltd | Oil-in-water type emulsified skin care preparation for external use |
| JP2012031068A (en) | 2010-07-28 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012136491A (en) | 2010-12-28 | 2012-07-19 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2018197203A (en) | 2017-05-23 | 2018-12-13 | 小林製薬株式会社 | Emulsion composition |
| JP2019156772A (en) | 2018-03-14 | 2019-09-19 | ロート製薬株式会社 | External composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021091609A (en) * | 2019-12-06 | 2021-06-17 | 小林製薬株式会社 | Emulsion composition |
-
2019
- 2019-12-06 JP JP2019221140A patent/JP7570174B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010270029A (en) | 2009-05-20 | 2010-12-02 | Shiseido Co Ltd | Oil-in-water type emulsified skin care preparation for external use |
| JP2012031068A (en) | 2010-07-28 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012136491A (en) | 2010-12-28 | 2012-07-19 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2018197203A (en) | 2017-05-23 | 2018-12-13 | 小林製薬株式会社 | Emulsion composition |
| JP2019156772A (en) | 2018-03-14 | 2019-09-19 | ロート製薬株式会社 | External composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024114984A (en) * | 2019-12-06 | 2024-08-23 | 小林製薬株式会社 | Emulsion composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021091610A (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7570174B2 (en) | Emulsion stabilization method | |
| JP7464358B2 (en) | Emulsion composition | |
| JP2018002685A (en) | Emulsion composition | |
| JP5855349B2 (en) | Oily preparation | |
| JP2024114984A (en) | Emulsion composition | |
| JP2022190025A (en) | External pharmaceutical composition | |
| JP7744739B2 (en) | Method for stabilizing allantoin and/or its derivatives | |
| JP2018193319A (en) | Emulsified composition | |
| JP7312527B2 (en) | emulsion composition | |
| JP7665329B2 (en) | Oil-in-water emulsion composition | |
| JP2017171643A (en) | External composition | |
| JP4972895B2 (en) | Urea formulation for external use | |
| JP6817733B2 (en) | Preparation for internal bleeding treatment | |
| JP2006117539A (en) | Oily ointment | |
| JP7465066B2 (en) | Emulsion stabilizer | |
| JP7421874B2 (en) | Open pore improver | |
| JP7092494B2 (en) | Water-in-oil emulsification composition | |
| JP7584886B2 (en) | Emulsion composition | |
| JP2017171642A (en) | Composition for external use | |
| JP7808421B2 (en) | External composition | |
| JP7479127B2 (en) | External Composition | |
| JP7642362B2 (en) | External pharmaceutical composition | |
| JP7398274B2 (en) | External composition | |
| JP7499024B2 (en) | External Composition | |
| JP6906899B2 (en) | Emulsified composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240716 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240910 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241008 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7570174 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |